Heron Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	155.1	144.29	127.04	107.67	86.35	88.64
Revenue Growth (YoY)	12.60%	13.57%	17.99%	24.70%	-2.59%	-39.28%
Cost of Revenue	52.32	55.33	100.24	133.38	175.64	209.52
Gross Profit	102.78	88.95	26.81	-25.71	-89.3	-120.88
Selling, General & Admin	101.18	100.48	119.82	143.55	127.13	101.68
Operating Expenses	101.18	100.48	119.82	143.55	127.13	101.68
Operating Income	1.6	-11.53	-93.02	-169.26	-216.43	-222.56
Interest Expense	-7.43	-6.03	-3.87	-2.47	-2.41	-1.9
Interest & Investment Income	3.55	3.55	3.36	1.64	0.43	3.63
Other Non Operating Income (Expenses)	1.95	4.83	1.18	-6.32	-0.4	-
EBT Excluding Unusual Items	-0.34	-9.18	-92.34	-176.42	-218.81	-220.83
Merger & Restructuring Charges	-	-	-4.2	-5.4	-1.4	-5.6
Gain (Loss) on Sale of Investments	0.01	0.01	-0	-	-	-
Asset Writedown	-1.91	-4.41	-0.62	-0.21	-0.48	-0.85
Other Unusual Items	-11.34	-	-13.4	-	-	-
Pretax Income	-13.58	-13.58	-110.56	-182.02	-220.68	-227.28
Net Income	-13.58	-13.58	-110.56	-182.02	-220.68	-227.28
Net Income to Common	-13.58	-13.58	-110.56	-182.02	-220.68	-227.28
Shares Outstanding (Basic)	158	152	138	109	98	91
Shares Outstanding (Diluted)	158	152	138	109	98	91
Shares Change (YoY)	3.91%	10.36%	26.87%	10.57%	8.48%	11.00%
EPS (Basic)	-0.09	-0.09	-0.80	-1.67	-2.24	-2.50
EPS (Diluted)	-0.09	-0.09	-0.80	-1.67	-2.24	-2.50
Free Cash Flow	-31.14	-24.24	-60.33	-148.74	-206.38	-191.63
Free Cash Flow Per Share	-0.20	-0.16	-0.44	-1.37	-2.10	-2.11
Gross Margin	66.27%	61.65%	21.10%	-23.87%	-103.42%	-136.38%
Operating Margin	1.03%	-7.99%	-73.22%	-157.20%	-250.65%	-251.09%
Profit Margin	-8.76%	-9.41%	-87.02%	-169.05%	-255.58%	-256.41%
Free Cash Flow Margin	-20.08%	-16.80%	-47.49%	-138.14%	-239.01%	-216.20%
EBITDA	3.96	-9.04	-90.12	-166.37	-213.41	-219.72
EBITDA Margin	2.55%	-6.26%	-70.93%	-154.52%	-247.15%	-247.88%
D&A For EBITDA	2.36	2.49	2.9	2.89	3.02	2.85
EBIT	1.6	-11.53	-93.02	-169.26	-216.43	-222.56
EBIT Margin	1.03%	-7.99%	-73.22%	-157.20%	-250.65%	-251.09%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.